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Abstract
Like formalin fixed paraffin embedded (FFPE) tissues, archived bone marrow aspirate slides are an abundant and untapped
resource of biospecimens that could enable retrospective molecular studies of disease. Historically, RNA obtained from
slides is limited in utility because of their low quality and highly fragmented nature. MicroRNAs are small (<22 nt) non-
coding RNA that regulate gene expression, and are speculated to preserve well in FFPE tissue. Here we investigate the use
of archived bone marrow aspirate slides for miRNA expression analysis in paediatric leukaemia. After determining the
optimal method of miRNA extraction, we used TaqMan qRT-PCR to identify reference miRNA for normalisation of other
miRNA species. We found hsa-miR-16 and hsa-miR-26b to be the most stably expressed between lymphoblastoid cell lines,
primary bone marrow aspirates and archived samples. We found the average fold change in expression of hsa-miR-26b and
two miRNA reportedly dysregulated in leukaemia (hsa-miR-128a, hsa-miR-223) was ,0.5 between matching archived slide
and bone marrow aspirates. Differential expression of hsa-miR-128a and hsa-miR-223 was observed between leukaemic and
non-leukaemic bone marrow from archived slides or flash frozen bone marrow. The demonstration that archived bone
marrow aspirate slides can be utilized for miRNA expression studies offers tremendous potential for future investigations
into the role miRNA play in the development and long term outcome of hematologic, as well as non-hematologic, diseases.
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Introduction
MicroRNA (miRNA) are a functionally-important class of small,
non-protein coding RNA that control gene expression post-
transcriptionally. This is an important layer of gene regulation
within all eukaryotic cells, and when perturbed can give rise to
disease [1,2,3]. At approximately 22 nucleotides long, the mature
miRNA is combined with RISC (RNA Induced Silencing
Complex) and Argonaute proteins to inhibit specific target
messenger RNA (mRNA) through base pair recognition [4,5]. In
silico analysis predicts over 1,000 miRNA genes within the human
genome [4], with each miRNA having the potential to regulate as
many as 200 targets, equalling over 30% of all human genes [6,7].
Aberrant expression of miRNAs has also been linked to critical
gene pathways in cancer development and progression.
Fresh tissue samples are the typically preferred source of DNA,
RNA and protein for disease analysis [2]. However with a current
absence of concomitant biobanking of disease specimens, re-
searchers are beginning to turn to alternative sources of biospeci-
mens such as those archived as part of routine clinical care.
Pathology and histology laboratories worldwide contain large
stocks of archived samples with potential utility for molecular
analysis [3] such as formalin-fixed paraffin-embedded (FFPE)
tissues and glass slide smears for haematological disorders.
Importantly, material archived as part of clinical care is usually
associated with extensive clinicopathological data, potentially
allowing for retrospective examination of specific molecular
markers and clinical disease associations [3]. Much interest has
therefore been placed on exploring the utility of various archived
biospecimens for molecular analyses.
In recent years the protocols for the extraction of DNA, mRNA,
miRNA and proteins from archived material have improved
enormously [2,8,9]. Previous reports have demonstrated the
isolation of PCR-amplifiable DNA and RNA from archival
unstained bone marrow slides [10,11], Giemsa-stained bone
marrow and peripheral blood smears [12,13,14], stored whole
peripheral blood [15] and dried blood Guthrie spots [16].
However, the isolation of sufficient amounts of DNA and RNA
for disease interrogation from FFPE samples remains challenging
[2]. Much attention therefore has been given to the possibility of
using archived FFPE samples for miRNA interrogation. It is
believed that miRNA are less susceptible to fragmentation and
degradation because of their small size [17,18]. Many studies have
demonstrated a good correlation between miRNA expression in
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FFPE and matched fresh-frozen tissues [3,8,18,19], with more
stable and consistent expression of miRNA in FFPE for
quantitative Real-Time PCR [9,17,20], microarray [19,21] and
deep sequencing analysis [22].
Unlike FFPE samples, the utility of archived bone marrow film
slides for miRNA expression studies has yet to be elucidated. The
current study is an exploratory investigation into the miRNA
expression relationship between archived slides and their matched
fresh-frozen tissue, using paediatric acute leukaemia samples (bone
marrow from acute lymphoblastic [ALL] and acute myeloid
[AML] patients).
We have investigated optimal miRNA extraction methods for
use with archived bone marrow aspirate slides and appropriate for
miRNA expression analysis. Our approach in investigating
miRNA expression on archived bone marrow smears could
equally be applied to study other hematologic diseases where
bone marrow and blood films are routinely archived. We can now
exploit a largely untapped source of samples available in most
pathology laboratories worldwide.
Results and Discussion
It has been shown in many studies that archived unstained
patient slide smear samples return good quality, amplifiable DNA
[10,11,12,13], but can have degraded total RNA [17,18]. The
innate small size of miRNAs however has been hypothesized to
decrease their chances of degradation during tissue processing
[17,18], and mature miRNAs may be less susceptible to
fragmentation due to their close association with the RISC protein
complex [1,19,21]. Here we have investigated the most efficient
RNA extraction methods which have applicability for miRNA
expression analysis; however a sufficient internal Reference gene
for normalization of our experimental expression data needed to
be first established.
Establishment of Reference Genes for Archived Bone
Marrow Samples
The accuracy of miRNA expression analysis is dependent on
the proper choice of endogenous controls, whereby inappropriate
normalization may lead to incorrect conclusions [23,24]. A
number of samples were used to identify internal reference
miRNAs that remain stably expressed, here for leukaemia and
hematopoietic diseases (Table S1). Model cell lines (n = 14) and
archived aspirate slides (n = 27) were used to evaluate the
expression stability of 14 putative miRNA reference genes utilizing
geNorm [25] and NormFinder (NF) [26] software (Table S2). The
best reference candidates identified here were hsa-miR-16 and
hsa-miR-26b (Figure 1). The expression of these miRNA are the
most consistent across the tissue types, disease states and
processing variables of the samples in our set (NF Ungrouped:
hsa-miR-16 M=1.14; NF Grouped by cancer status: hsa-miR-16
M=0.46 & hsa-miR-26b M=0.73; NF Grouped by Leukaemia
subtype: hsa-miR-16 M=0.57 & hsa-miR-26b M=0.68; geNorm:
hsa-miR-16 & hsa-miR-26b are equal at M=1.82). hsa-miR-16
and hsa-miR-26b have been previously reported as stable in
various human tissues and cell lines [23,27], in prostate and breast
cancer models [28] as well as in plasma and serum [29].
Optimization of miRNA Extraction from Archived Bone
Marrow Samples
To optimize RNA extraction from archived slide smear samples
several methods were trialled utilizing the Roche High Pure
miRNA isolation kit and TRIzol extraction. Unstained patient
smear samples from nine individuals (leukaemic and non-
leukaemic; Table S3) were used to evaluate the quality of six slide
miRNA extraction protocols (Table 1). We found here, as with
others, that longer Proteinase K digestion significantly increased
RNA yield (Figure 2A) [30,31,32]. The Roche overnight ‘isolation
of FFPE tissue’ protocol produced the highest total RNA yield in
this study (Mean 48.97 ng/ml (612.15 s.e.m.)). An equivalent
extraction protocol with a 3 hour digestion produced slightly lower
RNA yield for total RNA (Mean 34.7 ng/ml (66.29 s.e.m.)), and
significantly lower yield for small RNA extracts (Mean 14.77 ng/
ml (62.28 s.e.m.) Wilcoxon 2-tailed T-test p= 0.031). The
‘isolation of tissue’ protocols (homogenization of samples only)
were the least effective for RNA recovery, and returned
significantly lower yields then the FFPE overnight protocol (Mean
Small RNA: 10.78 ng/ml (64.66 s.e.m.) Wilcoxon 2-tailed T-test
p = 0.031; Total RNA: 10.14 ng/ml (62.97 s.e.m.) Wilcoxon 2-
tailed T-test p= 0.031).
To confirm these extraction techniques were suitable for
miRNA expression analysis, quantitative RT-PCR was used to
measure the expression of our identified reference miRNA (hsa-
miR-16) (Figure 2B). The methods of extraction utilizing sample
homogenization had the highest Ct results, which correspond
inversely to the lowest expression levels of hsa-miR-16, and the
lowest RNA yield. Values were improved by the addition of
Proteinase K where the kit ‘isolation of FFPE tissue’ total RNA
protocols returned the lowest Ct, therefore the highest miRNA
expression, and higher RNA yield (Total RNA 3 hr digestion
20.9960.89 s.e.m; Total RNA overnight digestion
21.6961.15 s.e.m). The TRIzol technique however provided both
a significantly lower total RNA yield in comparison to the
overnight kit protocol (Mean 11.37 ng/ml (64.51 s.e.m.) Wilcoxon
2-tailed T-test p= 0.008), as well as a higher Ct value
(23.5461.2 s.e.m) compared to all other protocols. TRIzol
extractions of total RNA from archived slides may potentially
cause the loss of small RNA species by inefficient RNA
precipitation compared to column-based isolation methods. It
has been recently suggested that loss of small RNA species in
TRIzol extractions may be due to differing GC content and
secondary structure [33]. The most efficient method of miRNA
extraction from archived slides found here was the ‘isolation of
FFPE tissue’ total RNA protocol, with an overnight Proteinase K
digestion.
Archived Slide Samples in Comparison to Fresh Bone
Marrow
The relationship in miRNA expression between matching
archived slides and flash-frozen bone marrow samples was
investigated to determine the utility of archived slides for
expression analysis. Twenty fresh bone marrow and matched
archived samples (Table S4) were analysed for hsa-miR-223, hsa-
miR-128a and hsa-miR-26b expression. We found the average
mean fold change in miRNA expression (using the Livak method
[34]) between fresh and matched archived samples for all three
miRNAs analysed to be minimal (Figure 3A, Average Fold
Change: hsa-miR-128a 0.12960.062 s.e.m.; hsa-miR-26b
0.37360.12 s.e.m.; hsa-miR-223 0.43860.154 s.e.m.). Similar
results have been reported recently for miRNA expression analysis
from FFPE sections [3,21] and Core biopsies [18].
To confirm the biological relevance of material extracted from
archived bone marrow smears, differential miRNA expression
analysis of hsa-miR-223 and hsa-miR-26b was performed on
leukaemic and non-leukaemic samples (Figure 3B; Table S4).
Human hsa-miR-223 has been identified as crucial to myeloid
regulatory networks [35,36] and dysregulated in leukaemia
[37,38,39]. Through our analysis here, we have identified hsa-
miRNA Expression from Patient Archived Slides
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miR-26b as a potential reference gene for future expression
studies. Hsa-miR-26b has also been reported previously as a stable
miRNA [27,28]. Both AML and ALL bone marrow samples in
this study showed substantial fold change differences in hsa-miR-
223 expression compared to non-leukaemic samples. The average
fold change in hsa-miR-223 expression between leukaemic and
non-leukaemic ALL samples was 2.71 (60.81 s.e.m.) from fresh
bone marrow, and 2.07 (60.83 s.e.m.) from archived slides.
Similar expression differences were observed in AML samples with
a fold change of 5.06 (61.99 s.e.m.) from fresh bone marrow
samples, and 4.36 (61.94 s.e.m.) from archived slides, confirming
observations from previous studies of hsa-miR-223 [38].
The differences we found in miRNA expression due to disease
state were far greater than the differences between archived slides
and their matching fresh bone marrow. However there are several
limitations encountered during the course of this study, such as
sample tissue and cellular heterogeneity (Table S3), as well as
degradation of samples. The miRNA we have identified here as
stable for certain hematopoietic studies have also previously been
shown as differentially expressed in other tissues. For example,
hsa-miR-26b has been implicated in carcinomas [40,41], and hsa-
miR-16 is reportedly dysregulated in Chronic Lymphoblastic
Leukaemia patients [42,43]. The careful selection of internal
reference genes for miRNA normalization is therefore critical, and
must be based on the sample types to be tested.
It has been proposed that alterations in miRNA expression play
a critical role in the pathophysiology of many, perhaps all, human
cancers [44]. Fresh frozen tissues are still seen as the gold standard
for disease studies [2], however the demands for large cohorts and
infinite resources means researchers are beginning to turn to the
archives of pathology and histology departments. To realize this
potential, development of proper methods of biomolecule extrac-
tion and analysis is warranted. In this regard FFPE samples for use
in miRNA expression profiling have been thoroughly investigated,
however the same cannot be said for archived slide smear samples.
This study to our knowledge is the first to attempt miRNA
expression analysis utilizing archived bone marrow aspirate slides.
We have developed a protocol for isolation of total RNA from
archival samples which includes an overnight Proteinase K
digestion followed by a column based kit extraction. This method
appears robust enough to allow the use of such samples in miRNA
association studies for disease classification, diagnosis and prog-
nosis.
Materials and Methods
Ethics Statement
This study was approved by the Royal Children’s Hospital
(RCH) Ethics Committee (HREC reference #27027B).
Samples
Samples used are existing archived fresh bone marrow
specimens and bone marrow films taken during diagnosis,
induction, remission and follow-up from paediatric acute leukae-
mia cases (Acute Lymphoblastic and Acute Myeloid) presented at
the Royal Children’s Hospital, Victoria, Australia. This cohort
consists of homogeneously treated patients with comprehensive
clinical annotations.
The films used during this study are archived, air-dried,
unstained bone marrow smear slides, with storage times varying
from 13 years to six months. Matched patient fresh bone marrows
(where used) were cryogenically frozen for no more than 5 years.
Figure 1. The stability of miRNA species expression in hematopoietic samples. The stability of miRNA species expression using 41 samples
of leukaemic and non-leukaemic cell lines, paediatric archived bone marrow aspirate slides (Table S1), and 14 potential miRNA candidates (Table S2).
geNorm and NormFinder (NF) were used to calculate the expression stability values for each miRNA tested. The most ‘stably’ expressed gene in a
sample group is that with an average expression stability value (M) closest to zero. The most stably expressed miRNA were; NF Ungrouped: hsa-miR-
16 M= 1.143; NF Grouped by Cancer Status: hsa-miR-16 M=0.457; NF Grouped by Leukaemia subtype: hsa-miR-16 M=0.573; geNorm: hsa-miR-16
and hsa-miR-26b are equal at M= 1.817.
doi:10.1371/journal.pone.0042951.g001
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Figure 2. A comparison of RNA extraction methods for the evaluation of RNA concentration (ng/ml) and miRNA expression from
archived bone marrow aspirate slides. The comparison of miRNA extraction methods from matched unstained archived bone marrow smears
(n = 6 or n= 8 patients; Table S3). Six different methods were used based on traditional TRIzol or using the Roche High Pure miRNA Column extraction
kit (Table 1). (A) Comparison of Total RNA yield from experimental extraction protocols. The average RNA concentration was measured by
NanoDrop (ng/ml 6s.e.m.). Kit Total RNA extraction methods with a Proteinase K digestion (‘FFPE protocol’) are higher in RNA yield compared to kit
methods without a digestion step (‘Tissue protocol’), or when extracting small RNA only. These methods are also significantly better than TRIzol
extractions. The archived slide extraction method with the highest RNA yield was the Roche kit ‘isolation from FFPE Tissue’ Total RNA extraction with
an overnight Proteinase K digestion. * Indicates RNA concentration is significantly different to the Kit Overnight FFPE: Total RNA protocol. (B)
Comparison of hsa-miR-16 expression from experimental extraction protocols. The average expression of our reverence gene (hsa-miR-16)
measured by qRT-PCR (raw Ct 6s.e.m.). Raw Ct value tracks with total RNA yield, whereby as the concentration of RNA increases the Ct value
decreases. This analysis shows extractions with a Proteinase K digestion return a lower Ct value compared to extractions without a digestion step.
TRIzol extractions also return a higher Ct value than the Proteinase K digestion protocols.
doi:10.1371/journal.pone.0042951.g002
miRNA Expression from Patient Archived Slides
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All patients were ,18 years of age. Control samples from bone
marrow of unrelated and unaffected children were analysed in
parallel, as well as multiple cell lines (K562 [45], DG-75 [46],
NALM-6 [47], Jeg-3, BEL, REH [48], CCRF-CEM [49], BeWo
[50], JWL, Jurkat [51], Kasumi-1 [52], THP-1 [53], MV-4-11 and
AML-193 [54]).
Extraction Methods
Before extraction, fresh bone marrow aspirates were processed
using a Ficoll-PaqueTM (GE Healthcare, Piscataway USA). The
white cell layer was immediately cryo-frozen or stored in
RNAlaterH (AmbionH by Life Technologies, Mulgrave, Victoria
AUST) prior to extraction.
Both fresh bone marrow and archived slides were extracted
using a TRIzol-based or kit-based method. The TRIzolH
(AmbionH, catalogue #AM9738) method was used as per the
manufacturer’s instructions. The Roche High Pure miRNA
Isolation Kit (Catalogue #05080576001, Dee Why, NSW AUST)
was used as per the manufacturer’s instructions where possible,
however modifications to the protocol were needed to improve the
total RNA yield (Table 1). After initial assessments, we chose to use
the ‘miRNA isolation from Tissue’ and ‘miRNA isolation from
FFPE’ kit extraction protocols (Table 1). The concentration and
purity of all RNA samples were assessed using the NanoDropH
ND-1000 spectrophotometer (Thermo Fisher Scientific Inc.,
Scorsby, Victoria AUST). All RNA was stored at 280uC.
Extraction Optimization Method
Nine patients (leukaemic and non-leukaemic) were used to
evaluate the quality of 6 slide extraction methods (Table 1; Table
S3). Six unstained archived slides, and two Giemsa-stained slides
were obtained for each patient. To standardize the amount of
starting material prior to extraction, the stained slides were cell
counted as an approximate measure of cell density on the
unstained slides. The volume of bone marrow added to each slide
at creation is kept equivalent, and therefore the volume of marrow
extracted from each slide was kept equivalent. Individual cell
counts are listed in Table S3. The whole material was used from
one glass slide from each patient to determine extraction
efficiency.
Both the TRIzol and kit methods were modified to include a
slide smear scraping step [12]. The cellular material was directly
dissolved in TRIzol or lysis buffer on the glass slide and scraped
using a Cell Scraper (NuncH) into a 1.5 ml microcentrifuge tube
prior to extraction.
Quantitative Real-Time PCR
Expression analysis used Applied Biosystems TaqManH micro-
RNA Assays for reverse transcription and Real-Time PCR (qRT-
PCR) (Applied BiosystemsH by Life Technologies, Mulgrave,
Victoria AUST). Amplification was measured by the Applied
Biosystems 7300 Sequence Detection System. Each singleplex
assay was performed according to the manufacturer’s instructions
with all samples run in triplicate. Replicates were omitted if
threshold cycle (Ct) standard deviation greater than 1, or where Ct
values were exactly 40. The threshold cycle (Ct) is defined as the
fractional cycle number at which the fluorescence passes a fixed
threshold [55]. All cDNA was stored at 220uC and appropriate
blanks were run.
The dynamic range and sensitivity of the TaqMan miRNA
assays was tested by using synthetic oligonucleotides of known
concentration to hsa-miR-16 and hsa-miR-26b to create a
Standard Curve (Figure S1A). Multiple real-time PCR runs for
both assays yielded consistent results for Range, Slope and R2
values, with a range of measurable values from 4.2861010
molecules/ml (Ct<5) to 36.8 molecules/ml (Ct<40).
Singleplex cDNA Reverse Transcription Conditions
Master Mix per sample: 0.15 ml 100 mM dNTPs, 1 ml Multi-
Scribe Reverse Transcriptase, 1.5 ml 106 Reverse Transcription
Buffer, 0.19 ml RNAse Inhibitor, 4.16 ml Nuclease-Free water, 3 ml
Reverse Transcription Primer. 10 ml of Master Mix was added to a
0.2 ml microcentrifuge tube, then 5 ml of RNA extract. All
samples were run on an Applied Biosystems 9700 Thermocycler
with the following PCR conditions: 30 min at 16uC, 30 min at
42uC, 5 min at 85uC, Hold indefinitely at 4uC.
Real Time PCR Conditions
Master Mix per sample: 10 ml TaqManH 26 Universal PCR
Master Mix, 7.67 ml Nuclease-Free water, 1 ml TaqManH
microRNA real-time assay primer. 18.67 ml of Master Mix was
added to an Applied Biosystems 96 well optical plate, then 1.33 ml
of reverse-transcribed RNA product. Real-time PCR conditions
Table 1. Modified protocols used for the extraction of RNA from archived bone marrow aspirate slides.
Method Name Product Used Protocol Slide Scraping Digestion RNA extraction
1: Kit Tissue: Small RNA Roche High Pure miRNA
Extraction Kit
‘Isolation from Tissue’ 300 ml Lysis buffer Homogenization Only Small RNA Only
2: Kit Tissue: Total RNA Roche High Pure miRNA
Extraction Kit
‘Isolation from Tissue’ 300 ml Lysis buffer Homogenization Only Total RNA
3: Kit FFPE: Small RNA Roche High Pure miRNA
Extraction Kit
‘Isolation from FFPE
Tissue’
200 ml Lysis buffer Proteinase K 3 hrs Small RNA Only
4: Kit FFPE: Total RNA Roche High Pure miRNA
Extraction Kit
‘Isolation from FFPE
Tissue’
200 ml Lysis buffer Proteinase K 3 hrs Total RNA
5: Kit Overnight FFPE:
Total RNA
Roche High Pure miRNA
Extraction Kit
‘Isolation from FFPE
Tissue’
200 ml Lysis buffer Proteinase K Overnight Total RNA
6: TRIzol: Total RNA TRIzol ‘Total RNA Isolation’ 400 ml TRIzol Homogenization Only Total RNA
The modified extraction protocols used in this study for the extraction of total RNA and small RNA from unstained archived bone marrow aspirate slides. Two main
methods were used, the Roche High Pure miRNA Isolation Kit and TRIzol. We followed two provided extraction protocols for the kit; ‘miRNA isolation from tissue’, and
‘miRNA isolation from FFPE tissue’. The methods provided by the manufacturers were modified to include a slide scraping step, and a digestion/homogenization step to
break down the slide material. The kit allows for the extraction of total RNA as well as small RNA only; both these methods were trialled here; samples listed in Table S3.
doi:10.1371/journal.pone.0042951.t001
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are as follows: 2 min at 50uC, 10 min at 95uC, 40 cycles of 15 sec
at 95uC then 1 min at 60uC.
Establishment of Reference Genes for Archived Bone
Marrow Samples
To establish the optimal reference genes, 14 cell line samples
were used and 27 archived patient bone marrow aspirate slides of
both leukaemic (9 ALL and 9 AML) and non-leukaemic (n = 9)
origin (Table S1). Each sample was measured using 14 RNA
assays for qRT-PCR (Applied BiosystemsH by Life Technologies).
The 14 RNA assays tested are listed in Table S2. geNorm [25] and
NormFinder [26] software packages were used to identify the most
stably expressed genes within this set. All raw Ct values for each
assay were first made linear and relative to each other using the
DCt method (outlined below, Equation 2) then input into the
software packages. Reference genes were designated as ‘stable’
when their expression was most consistent across the tested sample
types, disease states and extraction variables. The results obtained
from geNorm and NormFinder were confirmed independently
using DataAssistTM software (v.3.0 Applied Biosystems).
Expression Analysis
All data was collected using Microsoft Excel and analysed using
the LinRegPCR program v.11.0 [56]. All target and reference
Figure 3. The average fold change in miRNA expression between matched patient fresh bone marrow aspirates and archived bone
marrow slides. The average fold change in miRNA expression between matching time-point patient fresh bone marrow aspirates and archived slide
bone marrow aspirates (Table S4). (A) microRNA expression of matched patient fresh bone marrow and archived slide samples. Three
miRNA TaqMan assays were used (hsa-miR-128a, hsa-miR-26b, hsa-miR-223) and the Livak method for Fold Change analysis [34] to analyse the fold
change difference between fresh Bone marrow and matching archived slides. hsa-miR-128a and hsa-miR-223 have been previously reported to have
altered expression in leukaemia, whereas we have found here hsa-miR-26b is a stable reference. The overall difference in miRNA expression between
fresh bone marrow samples and their matching archived slide as shown here is negligible. (B) Difference in hsa-miR-223 expression in
archived and fresh leukaemic samples. Previously reported dysregulated miRNA hsa-miR-223 was used to analyse the fold change difference
between leukaemic and non-leukaemic samples, to gauge the biological relevance of archived specimens in comparison to fresh. All samples were
normalized to hsa-miR-26b. AML and ALL both showed fold change differences of hsa-miR-223 compared to non-leukaemic samples. The bone
marrow and archived slides showed similar expression in both AML (Bone Marrow: 5.161.99 s.e.m.; Slide: 4.461.94 s.e.m.) and ALL (Bone Marrow:
2.7160.81 s.e.m.; Slide: 2.160.83 s.e.m.).
doi:10.1371/journal.pone.0042951.g003
miRNA Expression from Patient Archived Slides
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genes had PCR efficiencies nearing 100% (Efficiency measures
.1.97), and each sample was within 5% of each other. All data
was statistically analysed using Graph Pad PRISMH V.5 and
confirmed using DataAssistTM software as above. The Livak
Method [34] was used for Fold Change analysis based on the
formulas below:
Equation 1: Where a Target Gene was Measured in a Test
Sample Relative to a Calibrator Sample, Normalized to
the Expression of a Reference Gene
DCt(test)~Ct(target, test){Ct(reference, test)
DCt(calibrator)~Ct(target, calibrator){Ct(reference, calibrator)
DDCt~DCt(test){DCt(calibrator)
FOLDCHANGE~2{DDCt :
Equation 2: Where the Effects of an Experimental
Treatment were Measured on the Expression of a
Candidate Gene, when only One Gene was Studied
DC’t~Ct, Treatmentx{Ct, No Treatment:
FOLDCHANGE~2{DC
0
t :
Archived Slide Samples in Comparison to Fresh Bone
Marrow
To evaluate archived bone marrow aspirate slides for miRNA
expression, 20 unstained archived slides were chosen, with
matching time-point fresh bone marrow available (Table S4). All
samples were extracted using the Roche High Pure miRNA
Isolation kit, ‘isolation from FFPE tissue’ Total RNA protocol with
3 hr Proteinase K digestion, which has been described here
previously. Following extraction each sample was analysed using
TaqMan miRNA assays hsa-miR-128a, hsa-miR-223 and hsa-
miR-26b. The resulting data were corrected for PCR efficiency
using LinRegPCR and analysed using the Relative quantitation
methods above. Where slide sample miRNA expression was
compared to its matching bone marrow (Figure 3A), Equation 2
was used without normalization to a reference gene. Where a
miRNA expression difference was determined between diseased
and non-diseased states (Figure 3B), Equation 1 was used with
normalization to hsa-miR-26b.
To verify these results were reflecting the disease states, rather
than due to differing Singleplex cDNA synthesis reactions, we
undertook an additional Multiplex validation step using Applied
Biosystems MegaplexTM Primer Pools (Human Pool A v2.1)
following the manufacturers protocol. This Megaplex contains RT
primers for simultaneous cDNA synthesis of 377 human miRNA
from the one RNA sample; therefore target and reference miRNA
can be analysed from the same RT reaction. This multiplex RT
reaction then served as the starting material for independent qRT-
PCR reactions (run on the same plate) using the miRNA and
methods previously mentioned. Comparison of the qRT-PCR
results for miRNA that were reverse transcribed as a group
(Multiplex) verses those transcribed individually (Singleplex)
showed no significant differences in qRT-PCR results (example:
Figure S1B). Additionally using a subset of AML samples, we
found no difference in the fold change results (leukaemic vs non-
leukaemic hsa-miR-223 expression normalized to hsa-miR-26b)
for Multiplex RT reactions as compared to Singleplex assays (Data
not shown), as has also been reported previously [57,58,59].
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